Please login to the form below

Not currently logged in
Email:
Password:

NICE

This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

A proposal by Sanofi to discount the cost to the NHS of its Dupixent drug for atopic dermatitis has not been enough to sway NICE, which has said it cannot back ... NICE said clinical experts (and the company) advise it should be used mainly as a

Latest news

  • NICE says OK to Keytruda for bladder cancer via the CDF NICE says OK to Keytruda for bladder cancer via the CDF

    The National Institute for Care and Health Excellence (NICE) has ruled that Keytruda can be made available as an option via the cancer drugs fund (CDF) for treating locally advanced or ... MSD’s KEYNOTE-045, the phase III study NICE based its decision

  • NHS seeks 'solution creators' from within pharma NHS seeks 'solution creators' from within pharma

    There has also been “a degree of convergence”among the people and bodies that work on assessing new medicines, he added, whether they be involved with NICE, the Cancer Drugs Fund

  • Merck and Pfizer set to win NICE backing for Bavencio Merck and Pfizer set to win NICE backing for Bavencio

    Merck and Pfizer set to win NICE backing for Bavencio. The PD-L1 inhibitor is being assessed for the treatment of mMCC patients. ... Additionally, NICE recommended Bavencio should be accessed via the Cancer Drugs Fund (CDF) for those with previously

  • NICE reverses its rejection of Eisai’s Lenvima NICE reverses its rejection of Eisai’s Lenvima

    NICE reverses its rejection of Eisai’ s Lenvima. The cost-effectiveness watchdog has now backed the thyroid cancer treatment. ... this type of thyroid cancer, we very much welcome this decision from NICE that demonstrates that these patients are no

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    NICE backs Roche’ s Gazyvaro after initial rejection. An undisclosed discount swayed the cost-effectiveness body. ... Previously, NICE also cleared Gazyvaro as a routine NHS treatment option for adults with chronic lymphocytic leukaemia (CLL).

More from news
Approximately 339 fully matching, plus 813 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 83 partially matching documents found.

Latest appointments

  • Professor Carole Longson moves from NICE to the ABPI Professor Carole Longson moves from NICE to the ABPI

    Professor Carole Longson moves from NICE to the ABPI. She joins the UK pharma body as its chief scientific officer. ... She most recently spent the 18 years at the National Institute for Health and Care Excellence ( NICE), where she has led the HTA

  • New health ministers and re-appointments after reshuffle New health ministers and re-appointments after reshuffle

    Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around

  • Virgo Health Education appoints new senior team Virgo Health Education appoints new senior team

    She has over 15 years' experience working in medical education and is a member of the ISMPP Ethics Committee, the NICE Implementation External Reference Group and part of the Royal Berkshire

  • Former NICE chair Sir Michael Rawlins to lead MHRA Former NICE chair Sir Michael Rawlins to lead MHRA

    Former NICE chair Sir Michael Rawlins to lead MHRA. He will take up his new role at the UK's medicines and devices regulator in December. ... Care Excellence (NICE) from its formation in 1999 to his departure last year.

  • ABPI appoints value and access manager ABPI appoints value and access manager

    initiatives. “ These include the implementation of the new PPRS scheme, working with NICE on value based assessment and helping our members with the changing NHS landscape whilst continuing to push for

More from appointments
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 50 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics